Brander, D. M., Roberts, A. W., Kipps, T. J., Ma, S., Anderson, M. A., Boyer, M., … Seymour, J. F. (2025). Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia. Hemasphere, 9(12), e70284. https://doi.org/10.1002/hem3.70284

Brander, Danielle M., Andrew W. Roberts, Thomas J. Kipps, Shuo Ma, Mary Ann Anderson, Michelle Boyer, Piers Blombery, et al. “Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.” Hemasphere 9, no. 12 (December 2025): e70284. https://doi.org/10.1002/hem3.70284.

Brander DM, Roberts AW, Kipps TJ, Ma S, Anderson MA, Boyer M, et al. Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia. Hemasphere. 2025 Dec;9(12):e70284.

Brander, Danielle M., et al. “Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.” Hemasphere, vol. 9, no. 12, Dec. 2025, p. e70284. Pubmed, doi:10.1002/hem3.70284.

Brander DM, Roberts AW, Kipps TJ, Ma S, Anderson MA, Boyer M, Blombery P, Popovic R, Roser J, Liu Z, Chyla B, Seymour JF. Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia. Hemasphere. 2025 Dec;9(12):e70284.